Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but a...
Saved in:
Published in | Journal of experimental & clinical cancer research Vol. 27; no. 1; p. 59 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
04.11.2008
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2-3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy. |
---|---|
AbstractList | A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2-3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy. Abstract A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2–3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy. |
ArticleNumber | 59 |
Audience | Academic |
Author | Copeman, Michael |
AuthorAffiliation | 1 Northern Beaches Cancer Service, Sydney, Australia |
AuthorAffiliation_xml | – name: 1 Northern Beaches Cancer Service, Sydney, Australia |
Author_xml | – sequence: 1 givenname: Michael surname: Copeman fullname: Copeman, Michael email: mcopeman@bigpond.net.au organization: Northern Beaches Cancer Service, Sydney, Australia. mcopeman@bigpond.net.au |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18983643$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kk1rHSEUhqWkNB_tursyUOhuEr9HN4U0JG1ooF20a3HUmWtw9KJzA_339WZCegdSXKjnvOfx4HtOwVFM0QHwHsFzhAS_QB3jrZSct7hrmXwFTp4jRwfnY3Bayj2EHEkk34BjJKQgnJIT8P1nTiHF0dkmu7JNsbhmTs3gc5nb4KNrXA5p9tH3zZByo-2Djqaqwy6O9eZiMjobH9Ok34LXgw7FvXvaz8Dvm-tfV9_aux9fb68u79qeIzq3vbYYI2O6QUJmoCWOc0OIZFRIxIlzkjDaE0I7bCkSnTScCi0pN4JIQiw5A7cL1yZ9r7bZTzr_UUl79RhIeVQ6z94Ep4iTcugpw9BWJkN6MBDhDmuqO4GhqKzPC2u76ydnjYtz1mEFXWei36gxPSjMEeaUVcCXBdD79B_AOmPSpPbGqL0xCneKyQr5uEBGXZv2cUhVaiZfjLqslhGB0ONT5y-o6rJu8qYOxuBrfFXw6aBg43SYNyWF3eyrz2vhxSI0OZWS3fDcP4JqP2gvdPzh8N_-6Z8mi_wFeLjOZw |
CitedBy_id | crossref_primary_10_1074_mcp_M117_067439 crossref_primary_10_1186_1471_2407_9_16 crossref_primary_10_1016_j_jprot_2018_04_005 |
Cites_doi | 10.1200/jco.2006.24.18_suppl.7178 10.1200/JCO.2006.07.5754 10.1200/JCO.2005.04.3299 10.1136/bmj.317.7161.771 10.1200/JCO.2005.08.409 10.1634/theoncologist.10-90003-1 10.1056/NEJMoa050736 10.1056/NEJMoa050753 10.1634/theoncologist.11-6-655 10.1016/j.lungcan.2005.11.001 10.1158/1078-0432.CCR-06-0260 10.1634/theoncologist.12-5-610 10.1200/JCO.2006.05.8073 10.3816/CLC.2006.n.022 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2008 BioMed Central Ltd. Copyright © 2008 Copeman; licensee BioMed Central Ltd. 2008 Copeman; licensee BioMed Central Ltd. |
Copyright_xml | – notice: COPYRIGHT 2008 BioMed Central Ltd. – notice: Copyright © 2008 Copeman; licensee BioMed Central Ltd. 2008 Copeman; licensee BioMed Central Ltd. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 5PM DOA |
DOI | 10.1186/1756-9966-27-59 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1756-9966 |
EndPage | 59 |
ExternalDocumentID | oai_doaj_org_article_3e99fb4520d54b51afc01272a4a78208 oai_biomedcentral_com_1756_9966_27_59 A191381145 10_1186_1756_9966_27_59 18983643 |
Genre | Research Support, Non-U.S. Gov't Journal Article Case Reports |
GeographicLocations | Australia |
GeographicLocations_xml | – name: Australia |
GroupedDBID | --- -5E -5G -A0 -BR 0R~ 29K 2WC 4.4 5GY 5VS AAFWJ AAJSJ ACGFO ACGFS ACRMQ ADBBV ADINQ ADRAZ ADUKV AENEX AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BFQNJ BMC C24 C6C CGR CS3 CUY CVF D-I DIK DU5 E3Z EBLON EBS ECM EIF EJD ESX F5P GROUPED_DOAJ H13 HYE IAO IEA IHR IHW INH INR IPNFZ ITC KQ8 M48 M~E NPM O5R O5S OK1 P2P PGMZT RBZ RIG RNS ROL RPM RSV SMD SOJ TR2 AAYXX CITATION AFGXO ABVAZ AFNRJ 5PM |
ID | FETCH-LOGICAL-b614t-bad221cc7f905c0d3e66c3395489163ee9354b33472d41879c648a946c83933d3 |
IEDL.DBID | RBZ |
ISSN | 1756-9966 0392-9078 |
IngestDate | Fri Oct 04 13:12:38 EDT 2024 Tue Sep 17 21:13:59 EDT 2024 Wed May 22 07:11:23 EDT 2024 Fri Feb 23 00:21:04 EST 2024 Fri Feb 02 04:36:22 EST 2024 Tue Aug 20 22:10:03 EDT 2024 Fri Sep 13 05:32:33 EDT 2024 Sat Sep 28 07:53:33 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b614t-bad221cc7f905c0d3e66c3395489163ee9354b33472d41879c648a946c83933d3 |
OpenAccessLink | http://dx.doi.org/10.1186/1756-9966-27-59 |
PMID | 18983643 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3e99fb4520d54b51afc01272a4a78208 pubmedcentral_primary_oai_pubmedcentral_nih_gov_2612645 biomedcentral_primary_oai_biomedcentral_com_1756_9966_27_59 gale_infotracmisc_A191381145 gale_infotracacademiconefile_A191381145 gale_healthsolutions_A191381145 crossref_primary_10_1186_1756_9966_27_59 pubmed_primary_18983643 |
PublicationCentury | 2000 |
PublicationDate | 2008-11-04 |
PublicationDateYYYYMMDD | 2008-11-04 |
PublicationDate_xml | – month: 11 year: 2008 text: 2008-11-04 day: 04 |
PublicationDecade | 2000 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of experimental & clinical cancer research |
PublicationTitleAlternate | J Exp Clin Cancer Res |
PublicationYear | 2008 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | 16921034 - J Clin Oncol. 2006 Aug 20;24(24):3831-7 17228019 - J Clin Oncol. 2007 Mar 1;25(7):760-6 16368866 - Oncologist. 2005;10 Suppl 3:1-10 15886311 - J Clin Oncol. 2005 May 10;23(14):3235-42 17062680 - Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6049-55 16800964 - Clin Lung Cancer. 2006 May;7(6):389-94 16478643 - Lung Cancer. 2006 Mar;51(3):335-45 9740561 - BMJ. 1998 Sep 19;317(7161):771-5 16014883 - N Engl J Med. 2005 Jul 14;353(2):133-44 16794244 - Oncologist. 2006 Jun;11(6):655-65 17522250 - Oncologist. 2007 May;12(5):610-21 16014882 - N Engl J Med. 2005 Jul 14;353(2):123-32 MS Tsao (58_CR13) 2006; 354 TJ Lynch Jr (58_CR14) 2007; 12 DM Jackman (58_CR7) 2007; 25 A Bezjak (58_CR4) 2006; 24 L Paz-Ares (58_CR9) 2006; 24 H Wakelee (58_CR1) 2005; 10 G Silvestri (58_CR15) 1998; 317 FA Shepherd (58_CR3) 2005; 353 GM Clark (58_CR10) 2006; 7 J-L Pujol (58_CR2) 2006; 51 G Giaccone (58_CR11) 2005; 23 G Giaccone (58_CR6) 2006; 12 S Ramalingam (58_CR5) 2006; 11 MS Tsao (58_CR12) 2005; 353 WL Akerley (58_CR8) 2006; 24 |
References_xml | – volume: 24 start-page: 408s year: 2006 ident: 58_CR8 publication-title: J Clin Oncol doi: 10.1200/jco.2006.24.18_suppl.7178 contributor: fullname: WL Akerley – volume: 25 start-page: 760 year: 2007 ident: 58_CR7 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.07.5754 contributor: fullname: DM Jackman – volume: 24 start-page: 368s year: 2006 ident: 58_CR9 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.04.3299 contributor: fullname: L Paz-Ares – volume: 354 start-page: 527 year: 2006 ident: 58_CR13 publication-title: N Eng J Med contributor: fullname: MS Tsao – volume: 317 start-page: 771 year: 1998 ident: 58_CR15 publication-title: BMJ doi: 10.1136/bmj.317.7161.771 contributor: fullname: G Silvestri – volume: 23 start-page: 3235 year: 2005 ident: 58_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.08.409 contributor: fullname: G Giaccone – volume: 10 start-page: 1 issue: Suppl 3 year: 2005 ident: 58_CR1 publication-title: Oncologist doi: 10.1634/theoncologist.10-90003-1 contributor: fullname: H Wakelee – volume: 353 start-page: 133 year: 2005 ident: 58_CR12 publication-title: N Eng J Med doi: 10.1056/NEJMoa050736 contributor: fullname: MS Tsao – volume: 353 start-page: 123 year: 2005 ident: 58_CR3 publication-title: N Eng J Med doi: 10.1056/NEJMoa050753 contributor: fullname: FA Shepherd – volume: 11 start-page: 655 year: 2006 ident: 58_CR5 publication-title: Oncologist doi: 10.1634/theoncologist.11-6-655 contributor: fullname: S Ramalingam – volume: 51 start-page: 335 year: 2006 ident: 58_CR2 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2005.11.001 contributor: fullname: J-L Pujol – volume: 12 start-page: 6049 year: 2006 ident: 58_CR6 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0260 contributor: fullname: G Giaccone – volume: 12 start-page: 610 year: 2007 ident: 58_CR14 publication-title: Oncologist doi: 10.1634/theoncologist.12-5-610 contributor: fullname: TJ Lynch Jr – volume: 24 start-page: 3831 year: 2006 ident: 58_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.8073 contributor: fullname: A Bezjak – volume: 7 start-page: 389 year: 2006 ident: 58_CR10 publication-title: Clin Lung Cancer doi: 10.3816/CLC.2006.n.022 contributor: fullname: GM Clark |
SSID | ssj0061919 |
Score | 1.8909817 |
Snippet | A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left... Abstract A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years... |
SourceID | doaj pubmedcentral biomedcentral gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 59 |
SubjectTerms | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Case Report Case studies Diagnosis Dosage and administration Drug therapy Erlotinib Erlotinib Hydrochloride Female Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Middle Aged Neoplasm Staging Patient outcomes Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - therapeutic use Quinazolines - administration & dosage Quinazolines - therapeutic use Risk factors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV29b9UwELdQh4oF8U2gFA9IsFhN_JVYTG1FVYGKGKjUzbIdB570moei8P9zZ-eFWgwsjLEvVny-8_0cn38m5K3Tipsw1IyrwJkMsE7pTNAsNH3faIBzPu3gX33Rl9fy0426uXPVF-aEZXrgrLgTEY0ZvFS87pX0qnFDwN1S7qRDqrd8zLdR-8VUnoNhVZCu9IDYqBki-oXUp-n0yVrGeMuQorQ46L4t4lOi8V8n6zVElemTd-LRxUPyYAGS9DR34BG5F8fH5PBq2Sp_Qj5_nWBeG7_Hnk45DzbSeUeHDcA9htiSxmm7mzfjxlMArnSfDEC34P7wFEeIchO0tbt1T8n1xcdv55dsuTmBeQi3M_Ou57wJoR1MrULdi6h1EALJ3QAOihiNAGUKIVveS7xvPGjZOSN1ALwkRC-ekYNxN8YXhOK-putiA9DBw6QK0WwIMUhd-9jWzseKfCj0Z39mlgyLvNVlDbiQRe1b1L7lrVWmIu_32l5fTMuSTv8teoajUbSfCsBa7GIt9l_WUpE3OJY2HzJdvduegsEAdmmkqsi7JIH-DV8d3HJMAbSBTFmF5FEhCX4Ziurn2Uz-dKwznQAEWJG2MKCiS2XNuPmRKL-R6E1L9fJ_6OAVuZ-SXvDfuDwiB_P0K74GZDX74-REvwFGZB0U priority: 102 providerName: Directory of Open Access Journals – databaseName: PubMed Central dbid: RPM link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaHhAXBOWVtlAfkODibuJXHHEqVauqaFEPVOrNsh2nRNpNqij8_46dZMHixjGxE8X2PL6JZz4j9MlIQSvX5IQKRwl3EKeoykniirouJMA5G3fw1z_k9R2_uRf3e0gstTAxad_Z9qzbbM-69lfMrXzcutWSJ7a6XV8E2ivJxWof7ZeMLSH6ZH4hIIineeTg-AlEfmrm8ymUXIGrlCQAfEJLIiJhqKoUk6FkJyl33yReKpL570z2zlGlSZR_eaWrl-jFDCfx-fTZr9Ce7w7Rs_W8Yf4afb8dwLp1D77Gw5QN6_HY46YF0EcCwsR-2PRj27UWA3zFS0oA3oARgCvfga8b4F391rxBd1eXPy-uyXx-ArHgdEdiTU1p4VzZVLlwec28lI6xQPEGoJB5XzHBLWO8pDUPp447yZWpuHSAmhir2Vt00PWdf49w2N00yhcAICyYVvBpjfOOy9z6MjfWZ-hrMn_6ceLK0IG9Om0BRdJhIXRYCE1LLaoMfVlme_dgDE6U_Lfrt7AayfvjjX540LOMaOarqrFc0LyGAYrCNC7ssFPDTaAHVBk6DWupp1LTnY7rc5AdQDAFFxn6HHsELYevdmYuVoDZCHxZSc-TpCdop0ua301i8mdgs8hlqEwEKBlS2gJ6EIm_Z7k_-u8nj9HzmO8SfovzE3QwDr_9BwBVo_0YlegJGgIePA priority: 500 providerName: National Library of Medicine – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9UwFA86QXwRv-2c2gdBX6JtvtowRKY4hnLFBy_sLSRpul24tlo70P9-56RdZ3A-tvmgSc7J-Z2e5HcIeWGVZNq3BWXSMyo8-Cm19or6smlKBXDOxQj-6os6WotPx_L4Mh3QPIG_rnTtMJ_Ueti-_v3zzztQ-LdR4Wv1BiygoojbKauo1NfJDSa4QHFfiSWkAI5CqWdunysaIXlorWuu8PpOcvV9m1isSOy_bN-L0UoPVP5loQ7vkNsztMwPJlm4S66F7h65uZqD5_fJ568D7HTdSWjyYToZG_Kxz9sNAECKaDMPw7YfN93G5QBl84vjAfkWNgR4Ch3YvQH66r_bB2R9-PHbhyM651KgDgzwSJ1tGCu9r1pdSF80PCjlOUe6NwCIPATNpXCci4o1AjOQeyVqq4XygKA4b_hDstP1XXhMcox02jqUACYcbLNg31ofvFCFC1VhXcjIfjJ_5sfEm2GQyTotAaUyuBAGF8KwykidkVcXs700jI5Krf6t-h5XI-k_vuiHEzMrnuFB69YJyYoGBihL23qMtjMrLFIF1hl5jmtppmuni76bA5AXQDOlkBl5GWugDMJXeztfXIDZQO6spOZeUhM01SfFjyYxuRzYLHIZqRIBSoaUlnSb00gCjtRvSsjd__b5hNyKZ1vwF7jYIzvjcBaeAoAa3bOoGOdGRhXC priority: 102 providerName: Scholars Portal |
Title | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18983643 http://dx.doi.org/10.1186/1756-9966-27-59 https://pubmed.ncbi.nlm.nih.gov/PMC2612645 https://doaj.org/article/3e99fb4520d54b51afc01272a4a78208 |
Volume | 27 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSIgL4k2gLDkgwcUi8Su2OLWIqgIt4kCliotlOw5dacmiKP3_nXGyKS7cuKyU9cSKxx7PNx77MyFvnJLMhK6iTAZGRYA4RZugaKjbtlYA53zK4K-_qtMz8flcnl-TRd_I4NdavQf_piiicsoaKs1tcochxzkG5sc_9pMuhAHpDo9FeGbx-UcFN062bzOHlHj7l9l58Un5fsk_HNDJA3J_Ro7l0dTVD8mt2D8id9dzbvwx-fJtgIms_xnbcpg2vsZy3JXdBvAdRTBZxmG7Gzf9xpeAVMt99r_cgr3DU-zBrQ1Q1-6Xe0LOTj59_3hK56sSqAf_OlLvWsbqEJrOVDJULY9KBc6RzQ3wH4_RcCk856JhrcALxoMS2hmhAgAkzlv-lBz0uz4-JyUmMp2ONWAFD7MouK8uxCBU5WNTOR8L8iHTn_090WJYJKrOS8BmLGrfovYta6w0BXm31_byYopDtPpb9Bh7I6s__QGjw852ZXk0pvNCsqqFBsradQGT6cwJh0yAuiCvsS_tdKp0MWd7BAMGwEotZEHeJgk0aPjq4OZzCaANpMbKJA8zSTDEkBU_m4bJdcO00RwgX0GabABlTcpL-s1F4vhGZjcl5Iv_UvZLci9tb8FVcHFIDsbhMr4CDDX6VVp7gN-10KtkSau00HUFxIsZMg |
link.rule.ids | 108,230,315,733,786,790,870,891,2115,2236,24346,24965,27957,27958,53827,53829,76169,76170 |
linkProvider | BioMedCentral |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagSMAF8SZQaA5IcDEkfiUWpxZRLbRbcWiliovlOE5baUmqKP3_zDgP1sCN465nrfizM_N5PfOZkLdWSaZdk1EmHaPCwT6l1E5Rl9d1roDOVeEEf32iVmfi27k8n7ItsBZmQrBrtgXu5yJBh0D0kwrO5YftAvVN8OpzMtnoC0r1EYKjokjpKSuo1LfJnQIVyHFXf_Bj9tiwhwgXgCzGkwTQPzr4oyx-E0WzIPq_uPYloMXJllvR6_AheTDRznR_fPJH5JZvH5O76-lg_Qk5-t6DF2wvfJ32Y9asT4cuba6AHFJkoqnvN90AAFUp0Nx0Th1IN-As4JNvISb20Ff30z4lZ4dfTj-v6HTPAq0gOA-0sjVjuXNFozPpspp7pRznKAUH5JF7r7kUFeeiYLXA28mdEqXVQjlgV5zX_BnZabvWvyApnoLa0udANCpwwRD7GuedUFnli8xWPiGfIvzM9aipYVDlOm6B-TSIvkH0DSuM1Al5P6O9_DBsYkr1t-kBzkbUf_ii6y_MtEwM91o3lZAsq2GAMreNw5N4ZoVFGcEyIXs4l2YsSV18gdmHBQNMJxcyIe-CBXoDeGpnp6IGQAN1tSLL3cgS3mIXNT8fl8nvgZW65MAXE1JECygaUtzSXl0GgXCUhVNCvvwvsPfIvdXp-tgcfz05ekXuhzwZ_Dtd7JKdob_xr4GMDdWb8Cb9ArCvMnw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKkSouiPJqoLQ5IMHFNPErsTj1wapQWlWIShUXy3acbcWSVFH4_4ydB2vgxm2znljyeDzzTez5jNBrLTiRts4w4ZZgZiFPKaUV2OZVlQuAcybs4J9fiNMr9umaX2-g5VQLM2qwrdcJ7qciQesV0Y0sODfv1gvUV8Grww_7_eCuqgdnUIoDiI4Ce0yPSYG5vIfuQ94uvPl_Ofo2uWxIIsINILPwyAH0jw7-qItfReEssP7Pvn2OaPFpy7XwtXiEHo64Mz0cDGUbbbjmMdo6H3fWn6Czyw7cYLN0VdoNx2Zd2rdpfQvoEHsomrpu1fagIZMCzk2nswPpCrwFPLkGgmIHfbU_9FN0tfjw9fgUjxctYAPRucdGV4Tk1ha1zLjNKuqEsJR6LjhAj9Q5STkzlLKCVMxfT24FK7VkwgK8orSiz9Bm0zZuB6V-G1SXLgekYcAHQ_CrrbNMZMYVmTYuQe8j_am7gVRDeZrruAUmVHntK699RQrFZYLeTtqeXwxZTCn-Fj3ysxH1H_5ou6UaV6WiTsraME6yCgbIc11bvxVPNNOeR7BM0L6fSzXUpM7OQB2CwQDUyRlP0Jsg4d2Btz49VjWANjyxViS5G0nCMrZR8_PBTH4PrJQlBcCYoCIyoGhIcUtzexMYwj0vnGD8xX8pex9tXZ4s1OePF2cv0YNwTsZ_Tme7aLPvfrpXAMZ6sxcW0i9IQTJQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prolonged+response+to+first-line+erlotinib+for+advanced+lung+adenocarcinoma&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Copeman%2C+Michael&rft.date=2008-11-04&rft.eissn=1756-9966&rft.volume=27&rft.spage=59&rft_id=info:doi/10.1186%2F1756-9966-27-59&rft_id=info%3Apmid%2F18983643&rft.externalDocID=18983643 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon |